Other
Conversion Therapy
0
Pipeline Programs↗
3
Active Trials↗
0
Companies Involved↗
Conversion Therapy is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
10
clinical trials
Unknown status7 · 70%
Recruiting2 · 20%
Not yet recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
Recruiting·—·Phase 2·NCT07353684·49 enrolled
Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06153368·30 enrolled
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05469061·17 enrolled
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05620498·60 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)